(Learn more about this study)
Initial CDAS Request Approval
Jun 1, 2020
Genome-wide association study (GWAS) for second primary lung cancer (SPLC) in PLCO
We aim to identify genetic risk factors associated second primary lung cancer (SPLC) among lung cancer patients. We will use outcome variable defined as: SPLC status (0: censored, 1: SPLC, 2: death from LC or other causes) and associated event time (e.g. diagnosis date, death date, etc.). We plan to use GWAS data (including genotyped data and imputed SNP data) for PLCO. We will run competing risk regression models (Fine and Gray regression and Cause-specific Cox hazards model) for each SNP adjusting for a set of covariates. The covariate list(s) will be provided. We plan to conduct two-stage analysis, where Stage 1 is focusing only on analyzing ~120 SNPs of interest (selected from the literature, list to be provided) and Stage 2 will be analyzeingthe entire GWAS data (genotyped and imputed).
To identify genetic variants associated with SPLC risk